Axelar AB is a Swedish biotechnology company that focuses its activities on research related to the insulin-like growth factor-1 (IGF-1) receptor inhibitors and their applications in important human diseases, especially cancer.

Axelar’s overall objective is to develop innovative small-molecule compounds that inhibit the IGF-1 receptor for treatment of IGF-1 receptor-dependent diseases where a significant unmet medical need still exists.

Axelar aspires to move these compounds into the clinic and then to enter partnerships that ensures global development and commercialization.

Latest news

Press release May 17, 2010
AXL1717 clinical data from ongoing phase I/II study in cancer patients will be released in connection with the ASCO meeting in Chicago, June 2010

Press release April 27, 2010
Axelar’s board strengthened

Press release November 13, 2009
Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA

Se also News